SEC Company Response from Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120) (AVTX) — Oct 3, 2018
Avalo Therapeutics, Inc. (AVTX) (CIK 0001534120)
Date: Oct. 3, 2018 · CIK: 0001534120 · Accession: 0001104659-18-060326
AI Filing Summary & Sentiment
File numbers found in text: 333-227227
Show Raw Text
CORRESP 1 filename1.htm 400 E. Pratt Street, Suite 606 Baltimore, Maryland 21202 October 3, 2018 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, DC 20549 Attn: Dorie Yale Re: Cerecor Inc. Registration Statement on Form S-3 Filed September 7, 2018, as amended October 2, 2018 File No. 333-227227 Ladies and Gentlemen: Cerecor Inc., a Delaware corporation (the “Registrant”), hereby requests that the Securities and Exchange Commission take appropriate action to make the Registration Statement on Form S-3 (File No. 333-227227) effective as of 4:30 p.m. Eastern Time, Friday, October 5, 2018, or as soon thereafter as practicable. Please advise our corporate counsel, Alexander M. Donaldson at (919) 781-4000, of any questions. The Registrant understands that the Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed public offering of the securities specified in the Registration Statement. Very truly yours, CERECOR INC. By: /s/ Joseph Miller Name: Joseph Miller Title: Chief Financial Officer